ArticleCell proliferation2015
Deferoxamine preconditioning to restore impaired HIF-1α-mediated angiogenic mechanisms in adipose-derived stem cells from STZ-induced type 1 diabetic rats.
Article in Cell proliferation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03085771 (Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes), which is not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes
Who cites it
32 citing papers in PubMed, 68 citations in OpenAlex.
- Short-term pretreatment with deferoxamine enhances the in vivo vascularization capacity of nanofat seeded onto dermal substitutes.EXCLI journal · 2026Article
- Article
- The regenerative journey: exploring stem cell roles from injury detection to tissue repair.Stem cell research & therapy · 2025Review
- Phytotherapeutic evaluation of rosehip seed and olive oils on wound healing: evidence from L929 cell culture and in vivo VEGF/TGF-β analysis.3 Biotech · 2025Article
- Metformin as a Modulator of Autophagy and Hypoxia Responses in the Enhancement of Wound Healing in Diabetic Rats.Inflammation · 2025Article
- Elucidating the effect of deferoxamine, a hypoxia mimetic agent, on angiogenesis restoration in endothelial progenitor cells (EPCs) from diabetic mice.Iranian journal of basic medical sciences · 2025Article
- Translational Challenges in Drug Therapy and Delivery Systems for Treating Chronic Lower Extremity Wounds.Pharmaceutics · 2024Review
- Mechanism of damage of HIF-1 signaling in chronic diabetic foot ulcers and its related therapeutic perspectives.Heliyon · 2024Review
- Engineered three-dimensional bioactive scaffold for enhanced bone regeneration through modulating transplanted adipose derived mesenchymal stem cell and stimulating angiogenesis.Frontiers in bioengineering and biotechnology · 2024Article
- Mitochondrial Metabolism and EV Cargo of Endothelial Cells Is Affected in Presence of EVs Derived from MSCs on Which HIF Is Activated.International journal of molecular sciences · 2023Article
- Restoring the Angiogenic Capacity of the Human Diabetic Adipose-derived mesenchymal stem cells Primed with Deferoxamine as a Hypoxia Mimetic Agent: Role of HIF-1α.Advanced pharmaceutical bulletin · 2023Article
- Guiding stem cells for cutaneous repair.Current research in pharmacology and drug discovery · 2023Review
- Chelating the valley of death: Deferoxamine's path from bench to wound clinic.Frontiers in medicine · 2023Article
- Losartan enhances the suppressive effect of pirfenidone on the bleomycin-induced epithelial-mesenchymal transition and oxidative stress in A549 cell line.Iranian journal of basic medical sciences · 2023Article
- Boosting therapeutic efficacy of mesenchymal stem cells in pulmonary fibrosis: The role of genetic modification and preconditioning strategies.Iranian journal of basic medical sciences · 2023Review
- Conditioned Medium of Adipose-Derived Mesenchymal Stem Cells as a Promising Candidate to Protect High Glucose-Induced Injury in Cultured C28I2 Chondrocytes.Advanced pharmaceutical bulletin · 2022Article
- Article
- Applications of tetrahedral DNA nanostructures in wound repair and tissue regeneration.Burns & trauma · 2022Review
- Article
- Hippocampal ornithine decarboxylase/spermidine pathway mediates HJournal of advanced research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBoth excessive and insufficient angiogenesis are associated with progression of diabetic complications, of which poor angiogenesis is an important feature. Currently, adipose-derived stem cells (ADSCs) are considered to be a promising source to aid therapeutic neovascularization. However, functionality of these cells is impaired by diabetes which can result from a defect in hypoxia-inducible factor-1 (HIF-1), a key mediator involved in neovascularization. In the current study, we sought to explore effectiveness of pharmacological priming with deferoxamine (DFO) as a hypoxia mimetic agent, to restore the compromised angiogenic pathway, with the aid of ADSCs derived from streptozotocin (STZ)-induced type 1 diabetic rats ('diabetic ADSCs'). MATERIALS AND
methodsDiabetic ADSCs were treated with DFO and compared to normal and non-treated diabetic ADSCs for expression of HIF-1α, VEGF, FGF-2 and SDF-1, at mRNA and protein levels, using qRT-PCR, western blotting and ELISA assay. Activity of matrix metalloproteinases -2 and -9 were measured using a gelatin zymography assay. Angiogenic potential of conditioned media derived from normal, DFO-treated and non-treated diabetic ADSCs were determined by in vitro (in HUVECs) and in vivo experiments including scratch assay, three-dimensional tube formation testing and surgical wound healing models.
resultsDFO remarkably enhanced expression of noted genes by mRNA and protein levels and restored activity of matrix metalloproteinases -2 and -9. Compromised angiogenic potential of conditioned medium derived from diabetic ADSCs was restored by DFO both in vitro and in vivo experiments.
conclusionDFO preconditioning restored neovascularization potential of ADSCs derived from diabetic rats by affecting the HIF-1α pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.